Summary & Overview
HCPCS G9912: Hepatitis B Assessment and Interpretation Before Anti-TNF Therapy
HCPCS Level II code G9912 captures assessment and interpretation of Hepatitis B virus (HBV) status prior to initiating anti–tumor necrosis factor (anti‑TNF) therapy. This pre‑treatment evaluation is clinically important because anti‑TNF agents can reactivate latent HBV, posing significant patient safety and care coordination implications. Nationally, standardized reporting of HBV screening and interpretation supports risk mitigation and aligns with efforts to improve biologic therapy safety.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and common sites of service, plus context for payer coverage considerations. The publication also outlines benchmarks and policy developments relevant to pre‑biologic infectious disease screening, and provides operational context for billing and coding teams.
This summary equips clinical leaders, billing managers, and policy analysts with the essential facts about G9912 — what the code represents, why HBV assessment matters before anti‑TNF therapy, which major payers are involved, and what readers can expect in the full piece regarding reimbursement benchmarks, documentation expectations, and clinical rationale. Data not available in the input is noted where applicable in subsequent sections.
Billing Code Overview
HCPCS Level II code G9912 documents that a patient's Hepatitis B virus (HBV) status was assessed and results interpreted prior to initiating anti-TNF (tumor necrosis factor) therapy. This service involves review of serologic testing and clinical interpretation to determine HBV infection, immunity, or susceptibility before starting biologic immunosuppressive treatment.
-
Service type: Pre-therapy infectious disease risk assessment and interpretation
-
Typical site of service: Outpatient clinic or infusion center where anti-TNF therapy is being considered or administered
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with moderate to severe rheumatoid arthritis is being evaluated by a rheumatology clinic prior to initiating anti–tumor necrosis factor (anti‑TNF) biologic therapy. The clinician obtains a detailed infectious risk history, reviews prior immunizations, and orders laboratory testing for hepatitis B virus (HBV) serology, including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti‑HBs), and hepatitis B core antibody (anti‑HBc total or IgG). The laboratory results are reviewed and interpreted by the ordering clinician before the first dose of anti‑TNF therapy is administered. If tests indicate prior exposure or active infection, the clinician documents interpretation, consults with infectious disease or hepatology as needed, and documents a management plan (e.g., antiviral prophylaxis, treatment, or vaccination) in the medical record. Typical documentation includes date/time of result review, specific serologic values, clinical interpretation (immune, susceptible, resolved infection, or active infection), and planned action. Typical sites of service are outpatient specialty clinics (rheumatology, dermatology, gastroenterology) and hospital outpatient infusion centers where biologic therapy is initiated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documented work or complexity for interpretation and management of HBV testing prior to anti‑TNF therapy is substantially greater than typical. |